Related Experiment Videos
Early prediction of neonatal hyperbilirubinemia
Insights
A newborn
Area of Science:
- Neonatal Medicine
- Pediatrics
- Clinical Chemistry
Background:
- Jaundice is a common condition in newborns.
- Early prediction of severe hyperbilirubinemia is crucial for timely intervention.
- Current prediction methods may have limitations in developing countries.
Purpose of the Study:
- To evaluate the predictive value of early serum bilirubin levels for subsequent hyperbilirubinemia and phototherapy in North Indian neonates.
- To establish a reliable and accessible prediction tool for neonatal jaundice management.
Main Methods:
- Prospective cohort study of 274 neonates in North India.
- Serum bilirubin measured at 18-24 hours post-birth and daily thereafter.
- Exclusion of neonates with risk factors like Rh incompatibility or congenital malformations.
Main Results:
- 12.8% of neonates developed hyperbilirubinemia; 19.3% received phototherapy.
- A serum bilirubin level > 3.99 mg/dL at 18-24 hours predicted hyperbilirubinemia with 67% sensitivity and 67% specificity.
- The same cut-off predicted the need for phototherapy with 64% sensitivity and 68% specificity.
Conclusions:
- Early serum bilirubin measurement at 18-24 hours can predict significant hyperbilirubinemia and the need for phototherapy in North Indian neonates.
- This prediction method identifies neonates at low risk, potentially reducing unnecessary readmissions.
- Further validation is needed, but the findings offer a valuable tool for neonatal care in developing countries.
Abstract:
The study aim was to predict, using serum bilirubin level measured 18 to 24 hours (SB, 18-24) after birth, the occurrence of peak serum bilirubin level > 15 mg/dL (hyperbilirubinemia) or the requirement of phototherapy, any time from the second to fifth postnatal day. The study was conducted on a prospective cohort of 274 neonates born in north India. The main outcome measures were (a) hyperbilirubinemia and (b) phototherapy. Serum bilirubin level was estimated at 18-24 hours of age and then daily from second to fifth postnatal day. Exclusion criteria were Rh incompatibility, asphyxia and life threatening congenital malformations; and neonates of women with gestational diabetes or history intake of drugs affecting the fetal liver. Hyperbilirubinemia was found in 12.8%; and 19.3% neonates received phototherapy. Dichotomous SB 18-24, using a cut-off of > 3.99 mg/dL, as the "prediction test" had the following sensitivity and specificity for predicting (a) hyperbilirubinemia: 67% and 67%, respectively, and (b) the treatment with phototherapy: 64% and 68%, respectively. We concluded that by using SB 18-24 as the "prediction test", approximately two-thirds of neonates were test negative and had about one in ten chances of re-admission for treatment of hyperbilirubinemia, if discharged. After further validation, our results will be of benefit to neonates delivered in developing countries.